ABL Bio Inc. Q3 operating loss of KRW 19.9 billion on revenue of KRW 8.8 billion
AI summary · Not investment advice
ABL Bio earned KRW 8.8 billion from operations in Q3 and lost KRW 19.9 billion from its main business, with KRW 41.6 billion earned from January to September.
Operating profit · 3 months
KRW -19.9 billion
Key facts
- Revenue (3 months)
- KRW 8.8 billion
- Net income (3 months)
- KRW -24.6 billion
- Period
- Q3 (cumulative 2026.01.01 ~ 2026.09.30)
- Revenue (prior-year 3 months)
- KRW 1.4 billion
- Revenue (year to date)
- KRW 41.6 billion
- Operating profit (prior-year 3 months)
- KRW -22.4 billion
- Operating profit (year to date)
- KRW -53.9 billion
- Net income (prior-year 3 months)
- KRW -21.3 billion
- Net income (year to date)
- KRW -54.3 billion
Commentary
AI commentary · Not investment advice
What happened
ABL Bio filed its quarterly report for the third quarter of 2026. The figures are on a consolidated basis, and the cumulative period runs from January 1 to September 30.
In the company's terms
Sales for the latest 3 months were KRW 8.76 billion. That compares with KRW 1.44 billion a year earlier, a change of +506.8%. Cumulative sales this year were KRW 41.60 billion.
What changes for shareholders
Operating profit (profit from the core business) for the latest 3 months was KRW -19.91 billion. A year earlier it was KRW -22.41 billion. Cumulative operating profit this year was KRW -53.94 billion.
Net income (the final profit after all costs and taxes) for the latest 3 months was KRW -24.62 billion. A year earlier it was KRW -21.30 billion. Cumulative net income this year was KRW -54.29 billion.
Comments
No comments yet
Comments from shareholders will appear here.
Ad
Verify your holdings and catch the next disclosure
Verify the stocks you hold and get new disclosures as app alerts.

App design sample
Get the next disclosure as an app alert
Get app alerts for new disclosures and stake changes on your watchlist
A